Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 1;35(9):17-18.
doi: 10.1097/01.JAA.0000854516.90788.a8.

Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease

Natalie Canales  1 , Tina Cao, Neeloufar Fakourfar, Mara Snee, Laura Tsu
Affiliations

Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease

Natalie Canales et al. JAAPA. .

Abstract

Direct-acting oral anticoagulants (DOACs) are an effective alternative to warfarin for patients with atrial fibrillation (AF) who require thromboembolic risk reduction. This article discusses the newly acceptable use of DOACs in patients with valvular AF, including native valvular heart disease and patients with bioprosthetic valves.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation . 2019;140(2):e125–e151.
    1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med . 2011;365(10):883–891.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med . 2009;361(12):1139–1151.
    1. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2013;369(22):2093–2104.
    1. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2011;365(11):981–992.

MeSH terms

LinkOut - more resources